{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:24:11Z","timestamp":1783517051737,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Early detection of active melanoma metastasis is crucial. Serum metabolomics may offer non-invasive biomarkers, but real-world applicability needs validation. This study aimed to identify \u00b9H-NMR-based serum metabolic signatures for active metastasis in a large clinical cohort. Serum from 963 melanoma patients (1698 samples) underwent \u00b9H-NMR spectroscopy. Patients were classified by active metastasis status. OPLS-DA and RFE followed by logistic regression models were developed on a patient-level training\/test split. Subgroup analyses assessed signatures related to Immune Checkpoint Inhibitor (ICI) therapy, brain metastases, and BRAF status. Models for active metastasis showed moderate test set discrimination (Area Under the Curve [AUCs]: OPLS-DA 0.609, RFE 0.630). The RFE-model highlighted seven significant metabolites: increased pyruvate, phenylalanine, acetoacetate, glutamate, glucose, and decreased histidine and citrate were associated with active metastasis. OPLS-DA yielded concordant metabolites. Subgroup analyses revealed distinct metabolic associations, e.g., for ICI therapy (citrate, RFE AUC 0.721) and BRAF status (acetate, RFE AUC 0.655), but limited performance for brain metastases (RFE AUC 0.553). \u00b9H-NMR serum metabolomics detects systemic metabolic alterations of active melanoma metastasis with moderate accuracy in a real-world setting. Identified disruptions in energy and amino acid metabolism offer pathobiological insights and warrant investigation for multimodal biomarker panels.<\/jats:p>","DOI":"10.1038\/s41598-026-37118-5","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:02:56Z","timestamp":1769770976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u00b9H-NMR serum metabolomic profiling from clinical routine identifies signatures of progressive melanoma metastasis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-4644","authenticated-orcid":false,"given":"Frank Friedrich","family":"Gellrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0859-2915","authenticated-orcid":false,"given":"Cosima","family":"Hufnagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-4599","authenticated-orcid":false,"given":"Alexander M.","family":"Funk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-0330","authenticated-orcid":false,"given":"Heidi","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5703-324X","authenticated-orcid":false,"given":"Sarah","family":"Hobelsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9094-4512","authenticated-orcid":false,"given":"Julian","family":"Steininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4054-4024","authenticated-orcid":false,"given":"Ricarda","family":"Rauschenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Garzarolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-6010","authenticated-orcid":false,"given":"Sophia","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4126-8248","authenticated-orcid":false,"given":"Lea","family":"P\u00f6schman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-0565","authenticated-orcid":false,"given":"Paula","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Sophie","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Feige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2543-852X","authenticated-orcid":false,"given":"Alpaslan","family":"Tasdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1869-5141","authenticated-orcid":false,"given":"Triantafyllos","family":"Chavakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-8475","authenticated-orcid":false,"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4340-9706","authenticated-orcid":false,"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5832-1673","authenticated-orcid":false,"given":"Peter","family":"Mirtschink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7625-343X","authenticated-orcid":false,"given":"Gerald","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"37118_CR1","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.22.00202","volume":"40","author":"C Garbe","year":"2022","unstructured":"Garbe, C. et al. Prognosis of patients with primary melanoma stage I and II according to American joint committee on cancer version 8 validated in two independent cohorts: implications for adjuvant treatment. J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol. 40, 3741\u20133749 (2022).","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol."},{"key":"37118_CR2","doi-asserted-by":"publisher","first-page":"115152","DOI":"10.1016\/j.ejca.2024.115152","volume":"215","author":"C. Garbe","year":"2025","unstructured":"Garbe, C. et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024. Eur. J. Cancer. 215, 115152 (2025).","journal-title":"Eur. J. Cancer"},{"key":"37118_CR3","first-page":"472","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald, J. E. et al. Melanoma staging: Evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 472\u2013492 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"37118_CR4","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199\u20136206 (2009).","journal-title":"J. Clin. Oncol."},{"key":"37118_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok, J. D. et al. Long-Term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol. 40, 127\u2013137 (2022).","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol."},{"key":"37118_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00432-023-05533-0","volume":"150","author":"M Reitmajer","year":"2024","unstructured":"Reitmajer, M. et al. Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017. J. Cancer Res. Clin. Oncol. 150, 15 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"37118_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.clinbiochem.2004.05.012","volume":"37","author":"R Harpio","year":"2004","unstructured":"Harpio, R. & Einarsson, R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin. Biochem. 37, 512\u2013518 (2004).","journal-title":"Clin. Biochem."},{"key":"37118_CR8","doi-asserted-by":"publisher","first-page":"e25318","DOI":"10.1097\/MD.0000000000025318","volume":"100","author":"J Xu","year":"2021","unstructured":"Xu, J., Zhao, J., Wang, J., Sun, C. & Zhu, X. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1\/PD-L1 therapy. Med. (Baltim). 100, e25318 (2021).","journal-title":"Med. (Baltim)."},{"key":"37118_CR9","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/00000658-199805000-00017","volume":"227","author":"WD Holder","year":"1998","unstructured":"Holder, W. D., White, R. L., Zuger, J. H., Easton, E. J. & Greene, F. L. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann. Surg. 227, 764\u2013771 (1998).","journal-title":"Ann. Surg."},{"key":"37118_CR10","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis, R. J. & Chandel, N. S. Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016).","journal-title":"Sci. Adv."},{"key":"37118_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell. Metab. 23, 27\u201347 (2016).","journal-title":"Cell. Metab."},{"key":"37118_CR12","first-page":"105","volume":"14","author":"AWL Bayci","year":"2018","unstructured":"Bayci, A. W. L. et al. Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma. Metabolomics Off J. Metabolomic Soc. 14, 105 (2018).","journal-title":"Metabolomics Off J. Metabolomic Soc."},{"key":"37118_CR13","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.3390\/cancers13112762","volume":"13","author":"S Di Donato","year":"2021","unstructured":"Di Donato, S. et al. A serum metabolomics classifier derived from elderly patients with metastatic colorectal cancer predicts relapse in the adjuvant setting. Cancers 13, 2762 (2021).","journal-title":"Cancers"},{"key":"37118_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-1-4939-2377-9_13","volume":"1277","author":"AHM Emwas","year":"2015","unstructured":"Emwas, A. H. M. The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. Methods Mol. Biol. Clifton NJ. 1277, 161\u2013193 (2015).","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"37118_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00216-006-0687-8","volume":"387","author":"Z Pan","year":"2007","unstructured":"Pan, Z. & Raftery, D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal. Bioanal Chem. 387, 525\u2013527 (2007).","journal-title":"Anal. Bioanal Chem."},{"key":"37118_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/metabo9070123","volume":"9","author":"AH Emwas","year":"2019","unstructured":"Emwas, A. H. et al. NMR spectroscopy for metabolomics research. Metabolites 9, 123 (2019).","journal-title":"Metabolites"},{"key":"37118_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/164_2022_612","volume":"277","author":"GAN Gowda","year":"2023","unstructured":"Gowda, G. A. N. & Raftery, D. Quantitative NMR methods in metabolomics. Handb. Exp. Pharmacol. 277, 143\u2013164 (2023).","journal-title":"Handb. Exp. Pharmacol."},{"key":"37118_CR18","doi-asserted-by":"publisher","first-page":"42324","DOI":"10.1038\/srep42324","volume":"7","author":"AP Santana-Filho","year":"2017","unstructured":"Santana-Filho, A. P. et al. NMR metabolic fingerprints of murine melanocyte and melanoma cell lines: application to biomarker discovery. Sci. Rep. 7, 42324 (2017).","journal-title":"Sci. Rep."},{"key":"37118_CR19","doi-asserted-by":"publisher","first-page":"e0240849","DOI":"10.1371\/journal.pone.0240849","volume":"15","author":"NJ Taylor","year":"2020","unstructured":"Taylor, N. J. et al. Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment. PloS One. 15, e0240849 (2020).","journal-title":"PloS One"},{"key":"37118_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1074\/mcp.M116.063313","volume":"16","author":"B Muqaku","year":"2017","unstructured":"Muqaku, B. et al. Multi-omics analysis of serum samples demonstrates reprogramming of organ functions via systemic calcium mobilization and platelet activation in metastatic melanoma. Mol. Cell. Proteom. MCP. 16, 86\u201399 (2017).","journal-title":"Mol. Cell. Proteom. MCP"},{"key":"37118_CR21","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.3390\/cancers15143708","volume":"15","author":"M Vilbert","year":"2023","unstructured":"Vilbert, M. et al. Analysis of the Circulating metabolome of patients with Cutaneous, mucosal and uveal melanoma reveals distinct metabolic profiles with implications for response to immunotherapy. Cancers 15, 3708 (2023).","journal-title":"Cancers"},{"key":"37118_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljae013","volume":"190","author":"J Pe\u00f1a-Mart\u00edn","year":"2024","unstructured":"Pe\u00f1a-Mart\u00edn, J. et al. Identification of novel biomarkers in the early diagnosis of malignant melanoma by untargeted liquid chromatography coupled to high-resolution mass spectrometry-based metabolomics: a pilot study. Br. J. Dermatol. 190, 740\u2013750 (2024).","journal-title":"Br. J. Dermatol."},{"key":"37118_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-025-03378-8","volume":"44","author":"S Costantini","year":"2025","unstructured":"Costantini, S. et al. Metabolomic signatures in liquid biopsy are associated with overall survival in metastatic melanoma patients treated with immune checkpoint inhibitor therapy. J. Exp. Clin. Cancer Res. 44, 119 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"37118_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12944-024-02169-y","volume":"23","author":"AB Zaid","year":"2024","unstructured":"Zaid, A. B. et al. Unraveling the controversy between fasting and nonfasting lipid testing in a normal population: a systematic review and meta-analysis of 244,665 participants. Lipids Health Dis. 23, 199 (2024).","journal-title":"Lipids Health Dis."},{"key":"37118_CR25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029\u20131033 (2009).","journal-title":"Science"},{"key":"37118_CR26","doi-asserted-by":"publisher","first-page":"djx071","DOI":"10.1093\/jnci\/djx071","volume":"109","author":"PW Stacpoole","year":"2017","unstructured":"Stacpoole, P. W. Therapeutic targeting of the pyruvate dehydrogenase Complex\/Pyruvate dehydrogenase kinase (PDC\/PDK) axis in cancer. JNCI J. Natl. Cancer Inst. 109, djx071 (2017).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"37118_CR27","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.biocel.2010.02.005","volume":"43","author":"S Mazurek","year":"2011","unstructured":"Mazurek, S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell. Biol. 43, 969\u2013980 (2011).","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"37118_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrc2981","volume":"11","author":"RA Cairns","year":"2011","unstructured":"Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer. 11, 85\u201395 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"37118_CR29","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s00018-013-1539-2","volume":"71","author":"LR Gray","year":"2013","unstructured":"Gray, L. R., Tompkins, S. C. & Taylor, E. B. Regulation of pyruvate metabolism and human disease. Cell. Mol. Life Sci. CMLS. 71, 2577\u20132604 (2013).","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"37118_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1194\/jlr.M082040","volume":"59","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Low ketolytic enzyme levels in tumors predict ketogenic diet responses in cancer cell lines in vitro and in vivo. J. Lipid Res. 59, 625\u2013634 (2018).","journal-title":"J. Lipid Res."},{"key":"37118_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10545-014-9704-9","volume":"37","author":"T Fukao","year":"2014","unstructured":"Fukao, T. et al. Ketone body metabolism and its defects. J. Inherit. Metab. Dis. 37, 541\u2013551 (2014).","journal-title":"J. Inherit. Metab. Dis."},{"key":"37118_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fonc.2019.00218","volume":"9","author":"P. Schwartsburd","year":"2019","unstructured":"Schwartsburd, P. Cancer-Induced reprogramming of host glucose metabolism: vicious cycle supporting cancer progression. Front. Oncol. 9, 218 (2019).","journal-title":"Front. Oncol."},{"key":"37118_CR33","doi-asserted-by":"publisher","first-page":"330","DOI":"10.4093\/dmj.2014.38.5.330","volume":"38","author":"TY Ryu","year":"2014","unstructured":"Ryu, T. Y., Park, J. & Scherer, P. E. Hyperglycemia as a risk factor for cancer progression. Diabetes Metab. J. 38, 330\u2013336 (2014).","journal-title":"Diabetes Metab. J."},{"key":"37118_CR34","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrc.2016.89","volume":"16","author":"F R\u00f6hrig","year":"2016","unstructured":"R\u00f6hrig, F. & Schulze, A. The multifaceted roles of fatty acid synthesis in cancer. Nat. Rev. Cancer. 16, 732\u2013749 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"37118_CR35","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1158\/0008-5472.CAN-11-4112","volume":"72","author":"N Zaidi","year":"2012","unstructured":"Zaidi, N., Swinnen, J. V. & Smans, K. ATP-Citrate lyase: A key player in cancer metabolism. Cancer Res. 72, 3709\u20133714 (2012).","journal-title":"Cancer Res."},{"key":"37118_CR36","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.3390\/cancers12113147","volume":"12","author":"L Pellerin","year":"2020","unstructured":"Pellerin, L. et al. Lipid metabolic reprogramming: role in melanoma progression and therapeutic perspectives. Cancers 12, 3147 (2020).","journal-title":"Cancers"},{"key":"37118_CR37","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.devcel.2021.04.013","volume":"56","author":"LA Broadfield","year":"2021","unstructured":"Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V. & Fendt, S. M. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev. Cell. 56, 1363\u20131393 (2021).","journal-title":"Dev. Cell."},{"key":"37118_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4062\/biomolther.2017.178","volume":"26","author":"YK Choi","year":"2018","unstructured":"Choi, Y. K. & Park, K. G. Targeting glutamine metabolism for cancer treatment. Biomol. Ther. 26, 19\u201328 (2018).","journal-title":"Biomol. Ther."},{"key":"37118_CR39","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1172\/JCI69600","volume":"123","author":"CT Hensley","year":"2013","unstructured":"Hensley, C. T., Wasti, A. T. & DeBerardinis, R. J. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 123, 3678\u20133684 (2013).","journal-title":"J. Clin. Invest."},{"key":"37118_CR40","doi-asserted-by":"publisher","first-page":"603837","DOI":"10.3389\/fcell.2020.603837","volume":"8","author":"Z. Wei","year":"2021","unstructured":"Wei, Z., Liu, X., Cheng, C., Yu, W. & Yi, P. Metabolism of amino acids in cancer. Front. Cell. Dev. Biol. 8, 603837 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"37118_CR41","doi-asserted-by":"publisher","first-page":"1123192","DOI":"10.3389\/fonc.2023.1123192","volume":"13","author":"Z. Wang","year":"2023","unstructured":"Wang, Z., Wu, X., Chen, H. N. & Wang, K. Amino acid metabolic reprogramming in tumor metastatic colonization. Front. Oncol. 13, 1123192 (2023).","journal-title":"Front. Oncol."},{"key":"37118_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2016.08.009","volume":"25","author":"GS Ducker","year":"2017","unstructured":"Ducker, G. S. & Rabinowitz, J. D. One-Carbon metabolism in health and disease. Cell. Metab. 25, 27\u201342 (2017).","journal-title":"Cell. Metab."},{"key":"37118_CR43","doi-asserted-by":"publisher","first-page":"8446","DOI":"10.3390\/ijms23158446","volume":"23","author":"T Srisongkram","year":"2022","unstructured":"Srisongkram, T. et al. Development of Sesamol Carbamate-L-Phenylalanine prodrug targeting L-Type amino acid Transporter1 (LAT1) as a potential antiproliferative agent against melanoma. Int. J. Mol. Sci. 23, 8446 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"37118_CR44","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3389\/fchem.2018.00243","volume":"6","author":"M Scalise","year":"2018","unstructured":"Scalise, M., Galluccio, M., Console, L., Pochini, L. & Indiveri, C. The human SLC7A5 (LAT1): the intriguing Histidine\/Large neutral amino acid transporter and its relevance to human health. Front. Chem. 6, 243 (2018).","journal-title":"Front. Chem."},{"key":"37118_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.canlet.2008.07.002","volume":"272","author":"G Neurauter","year":"2008","unstructured":"Neurauter, G. et al. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8. Cancer Lett. 272, 141\u2013147 (2008).","journal-title":"Cancer Lett."},{"key":"37118_CR46","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489\u2013495 (2011).","journal-title":"Lancet Oncol."},{"key":"37118_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1084\/jem.20151570","volume":"213","author":"LAJ O\u2019Neill","year":"2016","unstructured":"O\u2019Neill, L. A. J. & Pearce, E. J. Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med. 213, 15\u201323 (2016).","journal-title":"J. Exp. Med."},{"key":"37118_CR48","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.3390\/nu14224932","volume":"14","author":"CY Hwang","year":"2022","unstructured":"Hwang, C. Y. et al. Molecular mechanisms for ketone body Metabolism, signaling Functions, and therapeutic potential in cancer. Nutrients 14, 4932 (2022).","journal-title":"Nutrients"},{"key":"37118_CR49","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.4161\/cc.22137","volume":"11","author":"UE Martinez-Outschoorn","year":"2012","unstructured":"Martinez-Outschoorn, U. E. et al. Ketone body utilization drives tumor growth and metastasis. Cell. Cycle. 11, 3964\u20133971 (2012).","journal-title":"Cell. Cycle"},{"key":"37118_CR50","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","volume":"23","author":"R Haq","year":"2013","unstructured":"Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF. Cancer Cell. 23, 302\u2013315 (2013).","journal-title":"Cancer Cell."},{"key":"37118_CR51","first-page":"1591","volume":"159","author":"SA Comerford","year":"2014","unstructured":"Comerford, S. A. et al. Acetate Depend. Tumors Cell 159, 1591\u20131602 (2014).","journal-title":"Acetate Depend. Tumors Cell"},{"key":"37118_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2014.12.002","volume":"27","author":"ZT Schug","year":"2015","unstructured":"Schug, Z. T. et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell. 27, 57\u201371 (2015).","journal-title":"Cancer Cell."},{"key":"37118_CR53","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3390\/cells9102308","volume":"9","author":"JH Park","year":"2020","unstructured":"Park, J. H., Pyun, W. Y. & Park, H. W. Cancer metabolism: Phenotype, signaling and therapeutic targets. Cells 9, 2308 (2020).","journal-title":"Cells"},{"key":"37118_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/pcmr.12661","volume":"31","author":"GM Fischer","year":"2018","unstructured":"Fischer, G. M. et al. Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. Pigment Cell. Melanoma Res. 31, 11\u201330 (2018).","journal-title":"Pigment Cell. Melanoma Res."},{"key":"37118_CR55","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1021\/acs.analchem.4c04938","volume":"97","author":"H Altmann","year":"2025","unstructured":"Altmann, H. et al. Validating centralized biobanking workflows for NMR metabolomics using the PRIMA panel. Anal. Chem. 97, 2762\u20132769 (2025).","journal-title":"Anal. Chem."},{"key":"37118_CR56","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10858-011-9489-1","volume":"49","author":"P Bernini","year":"2011","unstructured":"Bernini, P. et al. Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks. J. Biomol. NMR. 49, 231\u2013243 (2011).","journal-title":"J. Biomol. NMR"},{"key":"37118_CR57","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/anie.201804736","volume":"58","author":"A Vignoli","year":"2019","unstructured":"Vignoli, A. et al. High-Throughput metabolomics by 1D NMR. Angew Chem. Int. Ed. 58, 968\u2013994 (2019).","journal-title":"Angew Chem. Int. Ed."},{"key":"37118_CR58","doi-asserted-by":"publisher","first-page":"9887","DOI":"10.1021\/ac5025039","volume":"86","author":"AC Dona","year":"2014","unstructured":"Dona, A. C. et al. Precision High-Throughput proton NMR spectroscopy of human Urine, Serum, and plasma for Large-Scale metabolic phenotyping. Anal. Chem. 86, 9887\u20139894 (2014).","journal-title":"Anal. Chem."},{"key":"37118_CR59","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1038\/nprot.2007.376","volume":"2","author":"O Beckonert","year":"2007","unstructured":"Beckonert, O. et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2, 2692\u20132703 (2007).","journal-title":"Nat. Protoc."}],"updated-by":[{"DOI":"10.1038\/s41598-026-57962-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37118-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37118-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37118-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:02:02Z","timestamp":1783515722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37118-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37118"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37118-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-57962-9","URL":"https:\/\/doi.org\/10.1038\/s41598-026-57962-9","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work the authors used Google\u2019s Gemini (Version 2.5) in order to improve readability and language. General prompts aiming to check and enhance clarity, spelling, and grammar, such as \"Review the following section for readability, spelling, and grammar,\" were utilized. After using this tool\/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Generative AI and AI-assisted technologies in the writing process"}}],"article-number":"5263"}}